Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A comprehensive survey of the mutagenic impact of common cancer cytotoxics.
Szikriszt B, Póti Á, Pipek O, Krzystanek M, Kanu N, Molnár J, Ribli D, Szeltner Z, Tusnády GE, Csabai I, Szallasi Z, Swanton C, Szüts D. Szikriszt B, et al. Among authors: szallasi z. Genome Biol. 2016 May 9;17:99. doi: 10.1186/s13059-016-0963-7. Genome Biol. 2016. PMID: 27161042 Free PMC article.
Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents.
Póti Á, Gyergyák H, Németh E, Rusz O, Tóth S, Kovácsházi C, Chen D, Szikriszt B, Spisák S, Takeda S, Szakács G, Szallasi Z, Richardson AL, Szüts D. Póti Á, et al. Among authors: szallasi z. Genome Biol. 2019 Nov 14;20(1):240. doi: 10.1186/s13059-019-1867-0. Genome Biol. 2019. PMID: 31727117 Free PMC article.
Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.
Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Swanton C. Juul N, et al. Among authors: szallasi z. Lancet Oncol. 2010 Apr;11(4):358-65. doi: 10.1016/S1470-2045(10)70018-8. Epub 2010 Feb 26. Lancet Oncol. 2010. PMID: 20189874 Free article.
Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers.
Guo J, Zhou Y, Xu C, Chen Q, Sztupinszki Z, Börcsök J, Xu C, Ye F, Tang W, Kang J, Yang L, Zhong J, Zhong T, Hu T, Yu R, Szallasi Z, Deng X, Li Q. Guo J, et al. Among authors: szallasi z. Cancer Res. 2021 Aug 15;81(16):4205-4217. doi: 10.1158/0008-5472.CAN-21-0086. Epub 2021 Jul 2. Cancer Res. 2021. PMID: 34215622 Free PMC article.
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.
Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, Miao C, Feng C, Gui B, Sztupinszki Z, Simoneau A, Xie N, Fazli L, Dong X, Azuma H, Choudhury AD, Mouw KW, Szallasi Z, Zou L, Kibel AS, Jia L. Tsujino T, et al. Among authors: szallasi z. Nat Commun. 2023 Jan 17;14(1):252. doi: 10.1038/s41467-023-35880-y. Nat Commun. 2023. PMID: 36650183 Free PMC article.
265 results